Grail entered a securities purchase agreement to raise approximately $325 million to fund commercial expansion and reimbursement efforts for its Galleri multi-cancer early-detection test. New and existing institutional investors joined the private placement; Samsung’s previously announced $110 million commitment remains a separate but material element of Grail’s financing outlook. Separately, Grail presented data showing Galleri added to standard screening increased cancer detection by sevenfold across several tumor types, strengthening the company’s commercial argument. The financing and clinical utility data together aim to extend Grail’s runway into 2030 while pushing payer and provider conversations on ctDNA screening.